Join Drs. Caimi and Sdrimas for a focused discussion on the coordination of CAR-T therapy between academic and community practices. As CAR-T use expands, ensuring seamless communication and shared responsibilities between care teams is essential. Using a real-world patient case, this episode explores how to navigate logistics, manage toxicities, and support patients in both settings—delivering collaborative, high-quality care. Learning Objectives:1. Understand the shared roles and responsibilities in CAR-T patient management across care settings 2. Identify communication strategies that support safe and effective care coordination 3. Explore real-world barriers and solutions to bridging academic and community practice collaborationClinical Pearls:Early and Appropriate Referral is Crucial: Community oncologists should refer patients early in the disease course. Being ineligible for transplant does not mean a patient is ineligible for CAR-T. Timely referral (i.e. before any other therapy is started unless clinically needed) allows for proper evaluation, manufacturing logistics, and bridging therapy if needed. Clear, Bidirectional Communication is Key to Safe Co-management: Successful shared care relies on: Identified point persons at both the academic and community sites (often including nurse coordinators).Timely updates about treatment timelines and toxicity events. Ideally, same day if a toxicity occurs. Weekly updates for treatment timelines.Use of standardized handoff templates and direct lines of communication to ensure continuity, safety, and efficiency in post-infusion monitoring.Empowering the Community Practice Enhances Access and Outcomes:Academic CAR-T centers, hematologists, nursing staff, and CAR-T coordinators educating community providers on late toxicities, infection risks, and long-term monitoring enables safe local care.Helpful resources:https://ashpublications.org/blood/article/141/20/2405/494965/Introduction-to-a-How-I-Treat-series-on-emergenthttps://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00094-9/abstracthttps://www.astct.org/Education/Practice-Guidelines
Join us for an insightful discussion with Drs. Natalia Neparidze and Saad Z. Usmani as we explore treatment strategies for relapsed multiple myeloma following BCMA-targeted therapy failure. With CAR T-cell therapy and bispecific antibodies revolutionizing myeloma treatment, clinicians are now faced with new challenges as patients relapse after BCMA-directed therapies. Through the case of a 62-year-old woman who relapsed one year post-BCMA CAR T-cell therapy, we will discuss mechanisms of resistance, treatment sequencing, and the role of novel agents like selinexor-pomalidomide-dexamethasone. This episode will provide hematologists with practical strategies to navigate post-BCMA treatment failure and optimize patient outcomes. Learning Objectives Understand mechanisms of resistance and progression following BCMA-targeted therapy. Explore non-BCMA treatment options, including alternative targets and novel agents. Recognize key factors influencing treatment selection and patient management.
Join us for an insightful discussion on hereditary hemorrhagic telangiectasia (HHT) with Drs. Hanny Al-Samkari and Adrienne Hammill as we explore the challenges in diagnosing and managing this genetic disorder. HHT is characterized by the development of bleeding nasal and gastrointestinal telangiectasias, as well as arteriovenous malformations (AVMs) in visceral organs and the central nervous system. Patients with HHT almost universally experience recurrent, often severe nose bleeding, and commonly develop gastrointestinal bleeding and complications of AVMs in the lung, liver, and/or brain. Through the case of a 40-year-old woman with recurrent bleeding episodes, we will explore the clinical features, diagnostic workup, and treatment options for HHT. This episode will provide valuable, evidence-based insights into how to approach the diagnosis and management of patients with HHT to improve outcomes and prevent complications. Learning Objectives: Identify the hallmark clinical features and diagnostic criteria for hereditary hemorrhagic telangiectasia (HHT). Explain the role of imaging and genetic testing in diagnosing HHT and assessing vascular malformations. Discuss management strategies, including proper pharmacologic management of chronic epistaxis and gastrointestinal bleeding, proper management of anemia, and management of AVMs.
Join us for an insightful discussion on thrombotic microangiopathy (TMA) in pregnancy with Drs. Richard Burwick and Shruti Chaturvedi as we navigate the complexities of diagnosing and managing hypertensive disorders in pregnancy. These conditions often present overlapping clinical and laboratory features, making timely and accurate intervention challenging. Through the case of a 32-year-old woman at 30 weeks' gestation with severe hypertension, headache, and new-onset thrombocytopenia, we will explore key diagnostic considerations, the distinguishing features of preeclampsia with severe features, Hemolysis, Elevated Liver enzymes, and Low Platelets (HELLP) syndrome, and TMA, and the best strategies for optimizing maternal and fetal outcomes in these high-risk situations. This episode offers practical, evidence-based insights to enhance the recognition and management of pregnancy-related TMA and hypertensive disorders. Learning Objectives: Differentiate between preeclampsia with severe features, HELLP syndrome, and TMA using clinical and laboratory findings. Identify the most appropriate diagnostic tests to confirm the underlying etiology in pregnant patients with hypertension and thrombocytopenia. Discuss immediate and long-term management strategies, including when to initiate delivery and the role of plasma exchange in suspected TMA.
In this episode of HemeTalks, Dr. Jill Johnsen and Dr. Michelle Sholzberg explore Von Willebrand Disease (VWD), the most common inherited bleeding disorder. The discussion delves into the disease's pathophysiology, diagnostic challenges, and the latest advancements in treatment. Learn about the complexities of diagnosing VWD, and discover we are working together to improve outcomes. This episode provides valuable insights for hematologists and healthcare professionals involved in the management of bleeding disorders. Learning Objectives: Understand the different ways that Von Willebrand Disease can present. Identify the challenges and best practices for diagnosing Von Willebrand Disease. Understand treatment options for Von Willebrand Disease and importance of personalized care.
Join us on HemeTalks as Dr. Christin DeStefano and Dr. Drew Helmer discuss the impact of military toxic exposures on the development of hematologic malignancies, including leukemia, lymphoma, and myeloma. Learn about the challenges of diagnosing and treating these cancers, advancements in research, and strategies for improving care for military members and veterans. Learning Objectives:Discuss challenges in studying the effects of toxic exposures commonly experienced during military service and their links to hematologic cancers. Understand the unique evaluation and treatment challenges for hematologic malignancies in veterans and active-duty military members. Explore hematology-specific research and initiatives aimed at improving early detection and care for this population.
Dr. Anjlee Mahajan (@anjleemd), Dr. Angela Weyand (@acweyand) and Dr. Michelle Sholzberg (@sholzberg ) delve into how current standards of care may contribute to disparities in the diagnosis and treatment of iron deficiency, particularly among female patients, as well as sharing compelling valuable insights into important considerations in addressing and overcoming these challenges to advance quality of care and improved outcomes for patients.Learning Objectives: To educate hematologists and coordinating healthcare providers, where possible, on…Some health inequities and challenges in providing comprehensive care to women with iron deficiency,Examples of identifying and treating patients with iron deficiency, andPractical steps we can all take to improve care of patients with iron deficiency.
Dr. Shakira Grant and Dr. Irum Kahn explore the fascinating history of stem cell transplants, beginning with its origins and milestones in the field such as the evolution of haploidentical transplants, a groundbreaking approach that has expanded donor options and improved outcomes for patients from diverse backgrounds. They then examine the clinical implications of these advancements, their transformative impact on patient care, and the power of diversity in donation.Learning Objectives: To educate hematologists on…Key barriers patients face in accessing stem cell transplantation, including financial, racial-ethnic, and logistical challenges,The importance of racial and ethnic diversity in stem cell donor registries and the steps being taken to improve it, andPolicy-level solutions and interventions aimed at reducing cost barriers for patients needing stem cell transplantation.
Dr. Rahma Warsame (@RWarsameMD) sits down with Dr. Margo Rollins to explore the critical clinical importance of diverse blood donors and unique challenges faced in recruiting and retaining a diverse donor pool. They then delve into practical strategies and opportunities to overcome these barriers. Join us to gain valuable insights into how enhancing donor diversity can significantly improve patient outcomes and promote health equity. Learning Objectives: To educate hematologists on…The importance of donor diversity in blood donations.Challenges faced in recruiting and retaining a diverse pool particularly from BIPOC communities.Strategies toward overcoming these barriers.
Are you a healthcare professional seeking clarity on the evolving treatments for sickle cell disease (SCD)? In this 20-minute episode, experts from cellular therapy and bone marrow transplantation (BMT) explore key updates in SCD care, including curative therapies, gene-editing innovations, and BMT approaches. They address practical challenges in integrating these treatments into practice and discuss strategies to improve access and outcomes. Tune in to discover how collaboration between cellular therapy and BMT providers is transforming care and paving the way for better patient experiences. Learning Objectives Understand recent advancements in curative therapies, including gene editing and BMT, for sickle cell disease. Identify key challenges and barriers to integrating new treatments into clinical practice for SCD patients. Explore collaborative care strategies between cellular therapy and BMT providers to improve patient outcomes and access.
Join us for an insightful podcast episode featuring the Co-Chairs of the upcoming 2024 ASH Annual Meeting, where we explore the planning process and strategic goals that shaped this year’s program. Discover how the Co-Chairs ensured the Education Program meets the diverse needs of the hematology community, and the unique challenges faced during the planning and how they were overcome. Gain exclusive insights into what makes this event the premier gathering for professionals in the field. Whether attending in person or virtually, find out how you can maximize your experience and apply the latest advancements to your practice or research.Learning Objectives:Understand the Planning Process: Learn about the strategic goals, collaborative efforts, and decision-making that guided the design of the Education Program for the 66th ASH Annual Meeting, ensuring it addresses the diverse needs of the hematology community.Overcome Planning Challenges: Learn about the specific challenges encountered during the planning of this year’s program and how they were effectively managed to deliver a meaningful experience for attendees.Impact on Practice and Research: Understand how this year’s program is designed to impact attendees' practices and research, fostering advancements in the field of hematology.
Join us as we explore blood transfusion safety, focusing specifically on Transfusion-Related Acute Lung Injury (TRALI) and Transfusion-Associated Circulatory Overload (TACO). Tailored for general hematologists with a foundational understanding of transfusion medicine, this session delves into the pathophysiology, clinical presentation, diagnostic criteria, and management strategies for TRALI and TACO. Through advanced discussions, participants will deepen their knowledge of these complications, enabling them to recognize, diagnose, and manage TRALI and TACO effectively in clinical practice.Learning Objectives:Gain a thorough understanding of the pathophysiology and clinical presentation of TRALI and TACO.Familiarize with the diagnostic criteria and differential diagnosis of TRALI and TACO.Develop effective management strategies for TRALI and TACO to ensure transfusion safety and enhance patient outcomes.
Are you a hematologist or a generalist provider seeking clarity on how to best counsel patients with sickle cell disease (SCD) who are interested in gene therapy? Join us for a podcast session focused on important patient considerations for gene therapy, tailored for SCD providers and clinicians. This session aims to provide practical insights to facilitate clear communication between providers, patients with SCD, and their families about treatment options.Learning ObjectivesUnderstand the Basics of Gene Therapy Treatments & SCD: By the end of the podcast, listeners will be able to identify some basic tenants of transformative treatments for sickle cell disease (SCD), focusing on how gene therapy treatments compare to other disease modifying treatments.Counseling Patients and Families: Listeners will be given suggestions on what key information to provide to patients and families that are interested in gene therapies, especially considering the build-up to gene therapy and also potential long-term effects.Enhance Communication Skills: This episode will suggest effective communication strategies to provide patients with both perspective and empathy while discussing gene therapy and other treatment options.
Speakers: Alexis Thompson, MD, and Sujit Sheth, MDDescription:For general hematologists with a foundational understanding of thalassemia, this episode discusses the changing demographics due to immigration and refugee resettlement. It covers the diagnosis process from newborn screening to older individuals, emphasizing genetic testing due to numerous mutations and varied phenotypes. The importance of correctly diagnosing older individuals previously misdiagnosed with iron deficiency refractory to treatment is highlighted. The episode also addresses regular transfusions, iron chelation, and monitoring for complications, along with advances in blood supply safety, reduced alloimmunization risks through extended typing, and MRI monitoring. Finally, novel agents in practice and development, including luspatercept, PK activators, and gene therapy, will be explored. Learning Objectives:Understand the changing landscape of thalassemia in the US. Revisit the state-of-the-art diagnostic and treatment approaches. Learn about novel therapeutics in the thalassemia field.
Dr. Azam Farooqui (@azamfarooqui ) and Dr. Monique Hartley-Brown (@DrMHB1) discuss therapeutic considerations regarding current and emerging agents for patients with multiple myeloma from underrepresented racial and ethnic groups. Coming Soon!Prepare to enhance your knowledge through the IMPACT II online learning module on ASH Academy On Demand! Participants will develop an increased ability to identify variations in factors influencing mortality and survival outcomes among individuals from racial and ethnic minority groups with multiple myeloma.Music: “Happy Medium” Zac Nelson (shutterstock.com). Licensed under Shutterstock: Standard License.
Dr. Azam Farooqui (@azamfarooqui )and Dr. Sikander Ailawadhi answer the question: Why do we need earlier diagnosis and intervention in patients with multiple myeloma from underrepresented racial and ethnic groups? Coming Soon!Prepare to enhance your knowledge through the IMPACT II online learning module on ASH Academy On Demand! Participants will develop an increased ability to identify variations in factors influencing mortality and survival outcomes among individuals from racial and ethnic minority groups with multiple myeloma.Music: “Happy Medium” Zac Nelson (shutterstock.com). Licensed under Shutterstock: Standard License.
Dr. Azam Farooqui (@azamfarooqui) and Dr. Urvi Shah (@UrviShahMD) identify factors that impact outcomes for patients with multiple myeloma from underrepresented racial and ethnic groups. Coming Soon!Prepare to enhance your knowledge through the IMPACT II online learning module on ASH Academy On Demand! Participants will develop an increased ability to identify variations in factors influencing mortality and survival outcomes among individuals from racial and ethnic minority groups with multiple myeloma.Music: “Happy Medium” Zac Nelson (shutterstock.com). Licensed under Shutterstock: Standard License.
Season 2: IMPACT II: Impacting Multiple Myeloma in All CommuniTiesUnlock insights into the treatment of multiple myeloma within underrepresented racial and ethnic populations with this series of three enlightening podcast episodes. Join experts from both academic and community oncology settings as they dive into critical aspects of clinical risk, survival outcomes, and treatment considerations.Episode 1: Uncover the factors influencing outcomes for multiple myeloma patients from underrepresented racial and ethnic groups with Dr. Shah.Episode 2: Join Dr. Ailawadhi in exploring a hypothetical scenario of equal conditions and envision how mortality and survival outcomes may differ for multiple myeloma patients from underrepresented groups. Episode 3: Gain valuable insights from Dr. Hartley-Brown as she discusses therapeutic considerations for both current and emerging agents tailored to multiple myeloma patients from underrepresented racial and ethnic backgrounds.Are you ready to expand your understanding of multiple myeloma treatment disparities? Listen to Season 2 of HemeTalks on Apple Podcasts, Spotify, Google Podcasts, or your preferred podcast platform! Don't forget to bookmark the ASH Podcast webpage for easy access.Coming Soon ASH Academy On Demand!Prepare to enhance your knowledge through the IMPACT II online learning module on ASH Academy On Demand! Participants will develop an increased ability to identify variations in factors influencing mortality and survival outcomes among individuals from racial and ethnic minority groups with multiple myeloma.Music: "PeriTune - Investigation2(Suspense-Royalty Free Music)" by PeriTune is licensed under CC BY 3.0.
Dr. Michael Diaz (@mdiazoncmd) and Dr. Namrata Chandhok (@NamrataChandhok) discuss the importance of genomic testing and how to understand and interpret test results when treating patients with myelodysplastic syndromes and clonal hematopoiesis. They also discuss the importance of selecting appropriate therapeutic agents to manage hematologic malignancies. This project is a collaboration between the American Society of Hematology and the Leukemia & Lymphoma Society. Access and complete the GENOM modules (for which you can claim CME and MOC credit) via ASH Academy On Demand! Music: "Happy Medium" performed by Zac Nelson, used under license from Shutterstock.
Dr. Michael Diaz (@mdiazoncmd) and Dr. James Blachly (@jamesblachly) discuss the importance of genomic testing and how to understand and interpret test results when treating patients with acute myeloid leukemia. They also discuss the importance of selecting appropriate therapeutic agents to manage hematologic malignancies. This project is a collaboration between the American Society of Hematology and the Leukemia & Lymphoma Society. Access and complete the GENOM modules (for which you can claim CME and MOC credit) via ASH Academy On Demand! Music: "Happy Medium" performed by Zac Nelson, used under license from Shutterstock.